- Home
- MSD vs STRO Comparison
MSD vs STRO Comparison
Compare MSD & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSD
- STRO
- Stock Information
- Founded
- MSD 1993
- STRO 2003
- Country
- MSD United States
- STRO United States
- Employees
- MSD N/A
- STRO N/A
- Industry
- MSD Trusts Except Educational Religious and Charitable
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MSD Finance
- STRO Health Care
- Exchange
- MSD Nasdaq
- STRO Nasdaq
- Market Cap
- MSD 159.9M
- STRO 162.9M
- IPO Year
- MSD N/A
- STRO 2018
- Fundamental
- Price
- MSD $8.02
- STRO $2.01
- Analyst Decision
- MSD
- STRO Strong Buy
- Analyst Count
- MSD 0
- STRO 7
- Target Price
- MSD N/A
- STRO $12.14
- AVG Volume (30 Days)
- MSD 70.2K
- STRO 984.5K
- Earning Date
- MSD 01-01-0001
- STRO 11-13-2024
- Dividend Yield
- MSD 11.26%
- STRO N/A
- EPS Growth
- MSD N/A
- STRO N/A
- EPS
- MSD N/A
- STRO N/A
- Revenue
- MSD N/A
- STRO $160,955,000.00
- Revenue This Year
- MSD N/A
- STRO N/A
- Revenue Next Year
- MSD N/A
- STRO N/A
- P/E Ratio
- MSD N/A
- STRO N/A
- Revenue Growth
- MSD N/A
- STRO 230.90
- 52 Week Low
- MSD $6.11
- STRO $1.67
- 52 Week High
- MSD $7.46
- STRO $6.13
- Technical
- Relative Strength Index (RSI)
- MSD 64.83
- STRO 46.04
- Support Level
- MSD $7.56
- STRO $1.72
- Resistance Level
- MSD $7.97
- STRO $2.08
- Average True Range (ATR)
- MSD 0.14
- STRO 0.14
- MACD
- MSD 0.05
- STRO 0.05
- Stochastic Oscillator
- MSD 98.53
- STRO 68.75
About MSD Morgan Stanley Emerging Markets Debt Fund Inc.
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.